Navigation Links
Primary Endpoint Achieved in CAVATAK Phase 2 Melanoma Trial
Date:9/18/2013

SYDNEY, Sept. 18, 2013 /PRNewswire/ -- Viralytics Limited (ASX: VLA, OTCQX: VRACY) has achieved the primary endpoint in its Phase 2 clinical trial of CAVATAKTM in the treatment of late stage melanoma patients (the CALM study).

The Phase 2 trial is a single arm study being conducted at 10 US sites and is designed to investigate the safety and efficacy of intratumoral CAVATAKTM (Coxsackievirus A21) in 54 evaluable1 patients with late stage (IIIc and IV) malignant melanoma.

The primary endpoint measured is immune related Progression Free Survival (irPFS) at six months after first dose of CAVATAK™. Progression Free Survival is the length of time, during and after treatment, that the patient lives with the cancer without it worsening. It includes patients that achieve a complete tumour response2, partial tumour response3 or stable disease4.

The primary endpoint of the study was to have 10 patients from a total of 54 evaluable patients reporting irPFS at six months after the first dose of CAVATAK™.  This was achieved after only 30 evaluable patients, representing an irPFS rate so far of 33%. 

"Achieving the primary endpoint of the CALM study before patient recruitment has been completed is very encouraging. In addition to the positive irPFS data we have observed responses in both injected and non-injected lesions," said Dr Robert Andtbacka, Lead Study Investigator from the Huntsman Cancer Institute in the US.

Dr Malcolm McColl, Chief Executive Officer of Viralytics said: "We are delighted to achieve this major milestone in the development of CAVATAK™. Given the excellent progress achieved to date and the encouraging feedback from key opinion leaders in the melanoma field we also believe it is now timely to consider the design of a randomised study in melanoma patients."

There are now 44 patients enrolled in the study with full enrollment forecast by the end of 2013.

Additional details about the Phase 2 CALM clinical trial can be found in the full ASX release issued by Viralytics:

http://www.asx.com.au/asx/statistics/displayAnnouncement.do?display=pdf&idsId=01444703

Full details of the clinical trial design can be found at the following website:

http://clinicaltrials.gov/show/NCT01227551

About Viralytics Ltd:

Viralytics is developing oncolytic virotherapy treatments for a range of cancers.  Viralytics' lead product, CAVATAK™, is a proprietary formulation of the common cold Coxsackievirus Type A21 (CVA21).  CVA21 binds to specific "receptor" proteins highly expressed on multiple cancer types including, but not limited to melanoma, prostate, lung, breast and bladder cancers; and multiple myeloma.  Intratumourally administered CAVATAKTM is currently being studied in a Phase 2 clinical trial in the treatment of Late stage Melanoma (the CALM study) at multiple cancer clinics in the US. 

Viralytics plans to commence a Phase I/II trial of CAVATAK™ being delivered systemically (intravenously). This trial referred to as the STORM (Systemic Treatment Of Resistant Malignancies) study will be undertaken in patients with melanoma, prostate, lung or metastatic bladder cancers. Viralytics has received regulatory approval from the UK Medicines and Healthcare products Regulatory Agency and will commence the STORM trial at three prominent UK sites later in 2013.

Based in Sydney Australia, Viralytics is listed on the Australian Securities Exchange (ASX: VLA) while its ADRs also trade under VRACY on the US OTCQX International market.  For more information on the company, please visit http://www.viralytics.comFor Viralytics Ltd:

US Investor Contacts:Dr. Malcolm McColl

Joshua Drumm, Ph.D. / Jason Rando+61 2 9988 4000

Tiberend Strategic Advisors, Inc.212.827.0020jdrumm@tiberend.com jrando@tiberend.com 1 Evaluable patients are those being on study for the six month tumour assessment visit or patients that have earlier withdrawn from the study due to progressive disease or for other reasons.

2 A complete tumour response (irRECIST 1.1) is the disappearance of the tumour burden.

3 A partial tumour response (irRECIST 1.1) is a reduction in the total tumour burden by greater that 30%.

4 Stable disease (irRECIST 1.1) is cancer that is neither decreasing nor increasing in extent or severity.


'/>"/>
SOURCE Viralytics Ltd.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Elcelyx Therapeutics NewMet for Type 2 Diabetes Meets Primary Endpoint in Phase 2b Study
2. Takeda EXAMINE Cardiovascular Safety Outcomes Trial of Alogliptin Met Primary Endpoint of Non-Inferiority Compared to Placebo in Addition to Standard of Care Showing No Increase in Cardiovascular Risk in Type 2 Diabetes Patients at High-Risk for Car
3. Rigels R343 Did Not Meet Primary Endpoint in Asthma Study
4. ARRY-502 Meets Primary And Key Secondary Endpoints In Asthma Study
5. TREATMENT OF PRIMARY LIVER CANCER: SARAH STUDY NOW AVAILABLE FOR ALL ELIGIBLE PATIENTS THROUGHOUT FRANCE
6. OxThera Strengthens Patent Portfolio for Orphan Disease - Primary Hyperoxaluria
7. Primary Efficacy and Safety Findings from Phase 3 Study of Janssens Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients
8. Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain
9. Lilly Announces Enzastaurin Phase III Study Did Not Meet Primary Endpoint in Diffuse Large B-Cell Lymphoma
10. Carena Launches 24/7 Virtual Care Delivery Service for Hospital Systems and Primary Care Clinics
11. Top-line Data Show AcelRx Pharmaceuticals ARX-04 Achieves Primary Endpoint in Dose-Finding Phase 2 Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... , May 24, 2016 ... beide primären Endpunkte und demonstriert ... in ‚ausgezeichneter plus guter , ...    ,      (Logo: http://photos.prnewswire.com/prnh/20130829/633895-a ... heute neue positive Daten von der MORA-Studie der ...
(Date:5/24/2016)... LAWRENCE, Mass. , May 24, 2016  NxStage ... medical technology company focused on advancing renal care, today ... Officer, plans to participate in the following schedule of ... will be made available at http://ir.nxstage.com/ . ... Jefferies Healthcare Conference NY, NY           Friday, ...
(Date:5/24/2016)... , May 24, 2016 ... de doble terapia del mundo, introduce catéteres para ... OrbusNeich, una compañía global especializada en ... vidas, ha expandido su cartera incluyendo productos para ... JADE™ y Scoreflex™ PTA son los dispositivos de ...
Breaking Medicine Technology:
(Date:5/24/2016)... ... May 24, 2016 , ... Women's ... , Roberta Jordan is a Certified Nurse Midwife who was born and raised ... then went on to complete her masters degree from the University of Mexico. ...
(Date:5/24/2016)... ... 24, 2016 , ... Educational opportunities, and therefore life chances, ... communities providing richer opportunities. Recognizing the key role of housing in this system, ... school choice policies; (c) school desegregation policies; (d) wealth-focused policies; and (e) housing-focused ...
(Date:5/24/2016)... ... 24, 2016 , ... Regenerative Medicine is being transformed by ongoing research and ... protocols and patient results as have been achieved with Okyanos Cell Therapy ... of care for patients worldwide. , As the Medical Advisory Chairman at Okyanos, Eric ...
(Date:5/24/2016)... ... 2016 , ... Backed by decades of experience, Metroloji Okulu ... the best suited solution to meet regulatory requirements. Their professional staff also performs ... Istanbul. , Metroloji Okulu specializes in MadgeTech’s line of medical and pharmaceutical ...
(Date:5/24/2016)... ... May 24, 2016 , ... American Gene Technologies ... to its board of directors. Otterstatter is co-founder, president and CEO of ... technological innovations that lead to broad-based healthcare solutions. , “Jon knows how to ...
Breaking Medicine News(10 mins):